The only problem is that the patent for Gendicine is in question, which I posted a link to several months ago. I'm not sure if it even matters at this point.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.